Back to Top
Charles H. Hood Foundation | Anida Pharma
By identifying innovative pediatric advancements and providing funding in the critical phases of development, we are able to expedite high-impact breakthroughs that improve the health and lives of millions.
portfolio_page-template-default,single,single-portfolio_page,postid-18158,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

Program Related Investment

Anida Pharma, Inc.

Multiple pediatric neuro-sensory diseases with high risk of life-long severe disability or death have no existing effective therapies. To address this unmet need Anida Pharma is developing a pipeline of treatments that utilize the potential of resolution biology toward novel treatment paradigms to prevent and restore neuro-sensory dysfunction. The company’s first target indication is Retinopathy of Prematurity. Follow-on indications include drug-induced hearing loss in chemotherapy treated children and neonatal brain injury. Learn more.